Background: Drug-related problems (DRPs) are widespread in hospitalized
neonates, but studies on the prevalence of DRPs in this population are limited.
The presence of clinical pharmacists on multidisciplinary teams helps prevent and
reduce DRPs.
Aim: This investigation aimed to identify and classify the incidence of DRPs in the
neonatal intensive care unit (NICU), to determine the determining factors
associated with DRPs and to document clinical pharmacists’ interventions,
outcomes, acceptance rates and clinical significance.
Method: A prospective descriptive hospital study was conducted from August to
November 2023 at the NICU of Children’s University Hospital, Assiut University,
Egypt. DRPs were classified using the Pharmaceutical Care Network of Europe
(PCNE) classification V9.1.
Results: Three hundred sixteen neonates were included in the study, with a mean
gestational age of 34 ± 4 weeks and a mean birth weight of 2.03 ± 0.85 kg. A total
of 1723 DRPs occurred among 283 neonates (89.6%), an average of 5.5 ± 5.1 DRPs
per patient. The main types were treatment effectiveness (P1) (799, 46.4%),
followed by others (P3) (469, 27.2%), and treatment safety (P2) (455, 26.4%).
The leading causes were dose selection (C3) (1264, 61.9%) and “other domain”
(C9) (543, 26.6%). Of the 2149 interventions introduced by pharmacists, 98.8%
were accepted and 93% were accepted, and fully implemented. As a result, 92% of
the DRPs were resolved. Both length of hospital stay and number of medications
were significantly associated with DRPs.
Conclusion: DRPs are common in the NICU; this study demonstrated the crucial
role of clinical pharmacists in identifying and resolving DRPs.